Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
Authors:
- Arnoud J. TempletonATArnoud J. Templeton
- Mairéad G. McNamaraMMMairéad G. McNamara
- Boštjan ŠerugaBŠBoštjan Šeruga
- Francisco E. Vera-BadilloFVFrancisco E. Vera-Badillo
- Priya AnejaPAPriya Aneja
- Alberto OcañaAOAlberto Ocaña
- Raya Leibowitz-AmitRLRaya Leibowitz-Amit
- Guru SonpavdeGSGuru Sonpavde
- Jennifer J. KnoxJKJennifer J. Knox
- Ben TranBTBen Tran
- Ian F. TannockITIan F. Tannock
- Eitan AmirEAEitan Amir
Top Cited Papers
Open Access
- 29 May 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 106 (6) , dju124
Abstract
Inflammation may play an important role in cancer progression, and a high neutrophil-to-lymphocyte ratio (NLR) has been reported to be a poor prognostic indicator in several malignancies. Here we quantify the prognostic impact of this biomarker and assess its consistency in solid tumors. A systematic review of electronic databases was conducted to identify publications exploring the association of blood NLR and clinical outcome in solid tumors. Overall survival (OS) was the primary outcome, and cancer-specific survival (CSS), progression-free survival (PFS), and disease-free survival (DFS) were secondary outcomes. Data from studies reporting a hazard ratio and 95% confidence interval (CI) or a P value were pooled in a meta-analysis. Pooled hazard ratios were computed and weighted using generic inverse-variance and random-effect modeling. All statistical tests were two-sided. One hundred studies comprising 40559 patients were included in the analysis, 57 of them published in 2012 or later. Median cutoff for NLR was 4. Overall, NLR greater than the cutoff was associated with a hazard ratio for OS of 1.81 (95% CI = 1.67 to 1.97; P < .001), an effect observed in all disease subgroups, sites, and stages. Hazard ratios for NLR greater than the cutoff for CSS, PFS, and DFS were 1.61, 1.63, and 2.27, respectively (all P < .001). A high NLR is associated with an adverse OS in many solid tumors. The NLR is a readily available and inexpensive biomarker, and its addition to established prognostic scores for clinical decision making warrants further investigation.Keywords
This publication has 115 references indexed in Scilit:
- Usefulness of Pretreatment Neutrophil to Lymphocyte Ratio in Predicting Disease-Specific Survival in Breast Cancer PatientsJournal of Breast Cancer, 2013
- Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancerClinical and Translational Oncology, 2012
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysisBritish Journal of Cancer, 2011
- Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancerBritish Journal of Cancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Immunity, Inflammation, and CancerCell, 2010
- Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03European Journal of Cancer, 2009
- Neutrophil/lymphocyte ratio and its association with survival after complete resection in non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2009
- Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastasesEuropean Journal of Cancer, 2009
- Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancerBritish Journal of Cancer, 2007